Subscribe to Newsletter

Subspecialties

Subspecialties Health Economics and Policy

The Economics of Gene Therapy

| Irv Arons

Gene and stem cell therapies hold the promise of restoring vision in patients with retinal diseases – but who should be paying for these treatments, and how?

Subspecialties Cataract

Eye, Robot

Ophthalmic surgery that incorporates robotic assistance holds the promise of surgeries that are “better than the best of humans”

Subspecialties Cornea / Ocular Surface

Success Second Time Round

Second corneal transplants are far more likely to be rejected than first-time grafts – but now that we know why, we might be able to prevent it

Subspecialties Professional Development

An Old Head on Young Shoulders

| Bala Ambati

Sitting Down With… Bala Ambati, Professor of Ophthalmology, Moran Eye Center, University of Utah, UT, USA.

Subspecialties Refractive

One Test to Rule Them All?

Measuring refractive error at six years of age may be the best way to predict which children will go on to become myopes

Subspecialties Cornea / Ocular Surface

Advancing OCT Angiography

| Sponsored by Heidelberg Engineering

OCT angiography (OCT-A) is poised to augment, and in many cases, replace traditional methods of examining the retinal and choroidal vasculature – once certain technical challenges are addressed.

Subspecialties Imaging & Diagnostics

Hot on the Trail

Thermography could offer a noninvasive way of assessing bleb function

Subspecialties Cataract

The High Price of Unnecessary Tests

Preoperative evaluation is not recommended for patients about to undergo cataract surgery – so why are ophthalmologists in the US continuing to order costly tests?

Subspecialties Cornea / Ocular Surface

Glaucoma and the Burden of Ocular Surface Disease

| Sponsored by Santen Pharmaceuticals

As many as six in every ten patients with glaucoma have ocular surface disease – and this can have a huge impact on their daily lives. We explore why, and what can be done.

teaser of 0515-803
Subspecialties Cornea / Ocular Surface

Current Treatment Options in Dry Eye Disease

| Sponsored by Santen Pharmaceuticals

Managing dry eye disease becomes disproportionately more difficult as the severity of the disease increases: artificial tears and lubricants are not enough to help patients with severe dry eye disease.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: